Skip to main content

  • Revolutionize the treatment paradigm for Diabetic Retinopathy

    R&D program with distinct and novel drug candidates with relevant modes-of-action in the diabetic retinopathy pathophysiology.

    Diabetic Retinopathy

  • Novaliq Transforms Ophthalmic Topical Therapies

    Our unique and versatile water-free technology revolutionizes ocular therapies.

    ABOUT US

  • EyeSol® is a novel drug category of drugs

    Our products are beneficial for the ocular surface, micro-dosed and non-preserved targeting multiple ophthalmic diseases with a “smart” eye drop.

    Products

  • Overcoming Limitations in Eye Care Therapies

    Our technology, opens completely new and exciting opportunities in the eye care for the relief and prevention of ophthalmological diseases in various indications for patients.

    EyeSol

  • We revolutionize dry eye drug therapies

    Two new and distinct drug products approved in Dry Eye Disease by the US FDA in 2023.

    Dry Eye Disease

  • We are Pioneers

    Our team of seasoned industry experts explores the world of water-free therapies to develop best-in-class ocular therapies. We expand into other eye care indications and topical therapeutics spaces.

    Team

  • Novel Drug Products Creation with new composition-of-matter IP

    EyeSol® Innovation generates Novel IP until at least.

    Novel Product Creation

Technology

EyeSol® is a novel drug category of water-free therapies

See More

Disease Areas & Pipeline

Novaliq offers an industry-leading portfolio of topical drug products that are water-free.

See More

Novaliq products

NovaTears®

NovaTears® is the first water-free eye drop based on EyeSol® developed for the treatment of dry eye. NovaTears® is CE certified since 2013 and successfully commercialized in Europe and in Australia/New Zealand by our partners.

read more

NovaTears®+Omega-3

NovaTears®+Omega-3 is the first eye drop containing high dose of Omega-3 fatty acids (0,2%).
read more

Lead product candidates

Our late-stage investigational drug developments provide unique therapeutic options for millions of diagnosed but untreated or undertreated dry eye patients:

CyclASol®

CyclASol® has the potential to change the way eye care practitioners treat patients with dry eye disease

read more

NOV03

Is the first drug with novel mechanism of action developed to treat the signs and symptoms of evaporative dry eye disease
read more

News & Media

Reach more about our latest press releases, key scientific
publications and other company resources

Novaliq is a private biopharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the worldwide first water-free ophthalmic technology.

About us